Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Teriparatide may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for Teriparatide SUN contains the active substance teriparatide that is used to make the bones stronger, and to reduce the risk of fractures by stimulating bone formation. Teriparatide SUN is used to treat osteoporosis in adults. Osteoporosis is a disease that causes your bones to become thin and fragile. This disease is especially common in women after the menopause, but it can also occur in men. Osteoporosis is also common in patients receiving corticosteroids.
e Teriparatide SUN Do not use Teriparatide SUN if you are allergic to teriparatide or any of the other ingredients of this medicine (listed in section 6) if you suffer from high calcium levels (pre-existing hypercalcaemia) if you suffer from serious kidney problems if you have ever been diagnosed with bone cancer or other cancers that have spread (metastasised) to your bones if you have certain bone diseases. If you have a bone disease, tell your doctor if you have unexplained high levels of alkaline phosphatase in your blood, which means you might have Paget's disease of bone (disease with abnormal bone changes). If you are not sure, ask your doctor if you have had radiation therapy involving your bones – if you are pregnant or breast-feeding. Warnings and precautions Teriparatide SUN may cause an increase in the amount of calcium in your blood or urine. V004
1
Talk to your doctor or pharmacist before or while using Teriparatide SUN if you have continuing nausea, vomiting, constipation, low energy, or muscle weakness. These may be signs there is too much calcium in your blood if you suffer from kidney stones or have a history of kidney stones if you suffer from kidney problems (moderate renal impairment). Some patients get dizzy or get a fast heartbeat after the first few doses. For the first doses, inject Teriparatide SUN where you can sit or lie down right away if you get dizzy. The recommended treatment time of 24 months should not be exceeded. Teriparatide SUN should not be used in growing adults. Children and adolescents Teriparatide SUN should not be used in children and adolescents (less than 18 years). Other medicines and Teriparatide SUN Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, because occasionally they may interact (e.g. digoxin/digitalis, a medicine used to treat heart disease). Pregnancy and breast-feeding Do not use Teriparatide SUN if you are pregnant, think you may be pregnant, or if you are breastfeeding. If you are a woman of child-bearing potential, you should use effective methods of contraception during use of Teriparatide SUN. If you become pregnant, Teriparatide SUN should be discontinued. Ask your doctor or pharmacist for advice before taking any medicine. Driving and using machines Some patients may feel dizzy after injecting Teriparatide SUN. If you feel dizzy you should not drive or use machines until you feel better. Teriparatide SUN contains sodium This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially "sodiumfree".
Teriparatide SUN Always use this medicine exactly as your doctor has told you to. Check with your doctor or pharmacist if you are not sure. The recommended dose is 20 micrograms given once daily by injection under the skin (subcutaneous injection) in the thigh or abdomen. To help you remember to take your medicine, inject it at about the same time each day. Inject Teriparatide SUN each day for as long as your doctor prescribes it for you. The total duration of treatment with Teriparatide SUN should not exceed 24 months. You should not receive more than one treatment course of 24 months over your lifetime. Teriparatide SUN can be injected at meal times. Carefully read the 'How to use the pre-filled pen' section as provided at the end of this leaflet. Injection needles are not included with the pen. Becton, Dickinson and Company pen needles can be used. V004
2
You should take your Teriparatide SUN injection shortly after you take the pen out of the refrigerator as described in PEN USER MANUAL at the end of this leaflet. For instructions for use video, please scan the QR code included in the Pen User Manual or use the link: https://www.pharmaqr.info/tpten. Put the pen back into the refrigerator immediately after you have used it. Use a new injection needle of 31 Gauge, 5 mm length for each injection and dispose of it after each use. Never store your pen with the needle attached. Never share your Teriparatide SUN pen with others. Your doctor may advise you to take Teriparatide SUN with calcium and vitamin D. Your doctor will tell you how much you should take each day. Teriparatide SUN can be given with or without food. If you use more Teriparatide SUN than you should If, by mistake, you have used more Teriparatide SUN than you should, contact your doctor or pharmacist. The effects of overdose that might be expected include nausea, vomiting, dizziness, and headache. If you forget or cannot take Teriparatide SUN at your usual time, take it as soon as possible on that day. Do not take a double dose to make up for a forgotten dose. Do not take more than one injection in the same day. Do not try to make up for a missed dose. If you stop taking Teriparatide SUN If you are considering stopping Teriparatide SUN treatment, please discuss this with your doctor. Your doctor will advise you and decide how long you should be treated with Teriparatide SUN. If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 4.
Like all medicines, this medicine can cause side effects, although not everybody gets them. The most common side effects are pain in limb (frequency is very common, may affect more than 1 in 10 people) and feeling sick, headache and dizziness (frequency is common). If you become dizzy (light-headed) after your injection, you should sit or lie down until you feel better. If you do not feel better, you should call a doctor before you continue treatment. Cases of fainting have been reported in association with Teriparatide SUN use. If you experience discomfort such as redness of the skin, pain, swelling, itching, bruising or minor bleeding around the area of the injection (frequency is common), this should clear up in a few days or weeks. Otherwise, tell your doctor as soon as possible. Some patients may have experienced allergic reactions soon after injection, consisting of breathlessness, swelling of the face, rash and chest pain (frequency is rare). In rare cases, serious and potentially life-threatening allergic reactions including anaphylaxis can occur. Other side effects include Common (may affect up to 1 in 10 people) increase in blood cholesterol levels depression neuralgic pain in the leg feeling faint irregular heart beats V004
3
–
breathlessness increased sweating muscle cramps loss of energy tiredness chest pain low blood pressure heartburn (painful or burning sensation just below the breast bone) being sick(vomiting) a hernia of the tube that carries food to your stomach low haemoglobin or red blood cell count (anaemia)
Uncommon (may affect up to 1 in 100 people) increased heart rate abnormal heart sound shortness of breath haemorrhoids (piles) accidental loss or leakage of urine increased need to pass water weight increase kidney stones pain in the muscles and pain in the joints. Some patients have experienced severe back cramps or pain which lead to hospitalisation increase in blood calcium level increase in blood uric acid level increase in an enzyme called alkaline phosphatase. Rare (may affect up to 1 in 1,000 people) reduced kidney function, including renal failure swelling, mainly in the hands, feet and legs. Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App store. By reporting side effects, you can help provide more information on the safety of this medicine.
Teriparatide SUN Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and pen after EXP. The expiry date refers to the last day of that month. Teriparatide SUN might be stored before the first opening at 25°C for 24 hours. Teriparatide SUN should be stored in a refrigerator (2°C to 8°C) at all times. You can use Teriparatide SUN for up to 28 days after the first injection, as long as the pen is stored in a refrigerator (2°C to 8°C). Do not freeze Teriparatide SUN. Avoid placing the pens close to the ice compartment of the refrigerator to prevent freezing. Do not use Teriparatide SUN if it is, or has been, frozen. V004
4
Each pen should be properly disposed of after 28 days, even if it is not completely empty. Teriparatide SUN contains a clear and colourless solution. Do not use Teriparatide SUN if solid particles appear or if the solution is cloudy or coloured. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment. 6.
What Teriparatide SUN contains The active substance is teriparatide. Each dose of 80 microliters contains 20 micrograms of teriparatide. Each pre-filled pen of 2.4 ml contains 600 micrograms of teriparatide (corresponding to 250 micrograms per ml. The other ingredients are glacial acetic acid (E260), anhydrous sodium acetate (E262), mannitol (E421), metacresol, and water for injections. In addition, hydrochloric acid (E507) and/or sodium hydroxide (E524) solution may have been added for pH adjustment. What Teriparatide SUN looks like and contents of the pack Teriparatide SUN is a clear and colourless solution. It is supplied in a cartridge contained in a disposable pre-filled pen. Each pen contains 2.4 ml of solution enough for 28 doses. It is available in packs of 1 or 3 pens. Not all package sizes may be marketed. Marketing Authorisation Holder Sun Pharma UK Limited 6 – 9 The Square Stockley Park Uxbridge UB11 1FW United Kingdom Manufacturers Sun Pharmaceutical Industries Europe B.V. Polarisavenue 87 2132 JH Hoofddorp The Netherlands Terapia S.A. Str. Fabricii nr 124 Cluj-Napoca, Judeţul Cluj Romania This leaflet was last revised in January 2025.
PEN USER MANUAL Teriparatide SUN 20 micrograms/80 microliters solution for injection in pre-filled pen V004
5
Instructions for use Before you use your new pen, please read the section Instructions for use completely. Follow the directions carefully when using the pen. Also read the package leaflet provided. For instructions for use video, please scan the QR code or use the link: https://www.pharmaqr.info/tpten.
Do not share your pen or your needles as this may risk transmission of infectious agents. Your pen contains 28 days of medicine. Teriparatide SUN Parts* Yellow Shaft Black Injection button Red Stripe Paper Tab
Green Body
Medicine Cartridge
Needle Small Needle Protector
White Cap Large Needle Cover
*Needles not included. The needle of 31 Gauge, 5mm length can be used. Ask your doctor or pharmacist which needle gauge and length are best for you. Always wash your hands before every injection. Prepare the injection site as directed by your doctor or pharmacist.
V004
6
1
Pull off white cap 2 Attach new needle
Pull off paper tab
Large Needle Cover
Push needle straight onto medicine cartridge.
Screw on needle until firmly attached.
Pull off large needle cover and save it.
3 Set dose Red stripe
Pull out black injection button until it stops.
Check to make sure red stripe shows.
If you cannot pull out the black inj ection button see Troubleshooting Problem E.
Small needle protector
Pull off small needle protector and throw away.
Note: After removal of inner needle protector, you may see drop(s) of medicine coming out of the needle. It is normal and will not affect your dose.
4 Inject dose
Push in black injection button until it stops. Hold it in and count to 5 s-l-o-w-l-y. Then pull the needle from skin.
Gently hold a fold of skin from thigh or abdomen and insert needle straight into skin.
V004
7
IMPORTANT 5 Confirm dose
After completing the injection Once the needle is removed from the skin, check to make sure the black injection button is all the way in. If the yellow shaft does not show, you have completed the injection steps correctly.
You should NOT see any of the yellow shaft. If you do and have already injected, do not inject yourself a second time on the same day. Instead, you MUST reset Teriparatide SUN (See Troubleshooting Problem A). 6 Remove needle Large needle cover
Put large needle Cover on needle.
Unscrew the needle all the way by giving the large needle cover 3 to 5 complete turns.
Pull off needle and throw Push white cap back on. away as directed by Place Teriparatide SUN your do ctor or pharmacist. in the refrigerator immediately after use.
The directions regarding needle handling are not intended to replace local, healthcare professional or institutional policies.
Teriparatide SUN 20 micrograms/80 microliters solution for injection in pre-filled pen
V004
8
Troubleshooting Problem A. The yellow shaft is still showing after I push in the black injection button. How do I reset my Teriparatide SUN ?
Solution To reset the Teriparatide SUN, follow the steps below. 1) If you have already injected, DO NOT inject yourself a second time on the same day. 2) Remove the needle. 3) Attach a new needle, pull off the large needle cover and save it. 4) Pull out the black injection button until it stops. Check to make sure the red stripe shows. 5) Pull off the small needle protector and throw away. 6) Point the needle down into an empty container. Push in the black injection button until it stops. Hold it in and count to 5 s-l-o-w-l-y. You may see a small stream or drop of fluid. When you have finished, the black injection button should be all the way in. 7) If you still see the yellow shaft showing, please contact your doctor or pharmacist 8) Put the large needle cover on needle. Unscrew the needle all the way by giving the needle cover 3 to 5 complete turns. Pull off needle cover and throw away as directed by your doctor or pharmacist. Push the white cap back on, and place Teriparatide SUN in the refrigerator. You can prevent this problem by always using a NEW needle for each injection, and by pushing the black injection button all the way in and counting to 5 s-l-o-w-l-y.
V004
9
B. How can I tell if my Teriparatide SUN works?
C. I see an air bubble in my Teriparatide SUN. D. I cannot get the needle off.
E. What should I do if I cannot pull out the black injection button?
The Teriparatide SUN is designed to inject the full dose every time it is used according to the directions in the section How to use. The black injection button will be all the way in to show that the full dose has been injected from the Teriparatide SUN. Remember to use a new needle every time you inject to be sure your Teriparatide SUN will work properly. A small air bubble will not affect your dose nor will it harm you. You can continue to take your dose as usual. 1) Put the large needle cover on the needle. 2) Use the large needle cover to unscrew the needle. 3) Unscrew the needle all the way by giving the large needle cover 3 to 5 complete turns. 4) If you still cannot get the needle off, ask someone to help you.
Change to a new Teriparatide SUN to take your dose as directed by your doctor or pharmacist. This indicates that you have now used all the medicine that can be injected accurately even though you may still see some medicine left in the cartridge. Cleaning and Storage
Cleaning Your Teriparatide SUN
V004
10
Disposal of Pen Needles and Teriparatide SUN Device
V004
The Teriparatide SUN contains 28 days of medicine. Do not transfer the medicine into a syringe. Write down your first injection date on a calendar. Read and follow the instructions in the Information for the Patient leaflet for using the medicine. Check the Teriparatide SUN label to make sure you have the correct medicine. and that it has not expired. Contact your doctor or pharmacist if you notice any of the following: The Teriparatide SUN appears damaged
11
Teriparatide SUN 20 micrograms/80 microliters solution for injection in pre-filled pen comes as injection containing 20mcg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Teriparatide SUN 20 micrograms/80 microliters solution for injection in pre-filled pen is teriparatide.
Medicines with the same active substance, strength and form include: Forsteo 20 micrograms/80 microlitres solution for injection in pre-filled pen, Movymia 20 micrograms/80 microliters solution for injection, Terrosa 20 micrograms/80 microliters solution for injection. In total there are 4 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Teriparatide SUN 20 micrograms/80 microliters solution for injection in pre-filled pen, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Teriparatide SUN is indicated in adults.
Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5.1). In postmenopausal women, a significant reduction in the incidence of vertebral and non- vertebral fractures but not hip fractures has been demonstrated.
Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.1).
Posology
The recommended dose of Teriparatide SUN is 20 micrograms administered once daily.
The maximum total duration of treatment with Teriparatide SUN should be 24 months (see section 4.4). The 24-month course of Teriparatide SUN should not be repeated over a patient's lifetime.
Patients should receive supplemental calcium and vitamin D supplements if dietary intake is inadequate.
Following cessation of Teriparatide SUN therapy, patients may be continued on other osteoporosis therapies.
Special populations
Patients with renal impairment
Teriparatide SUN must not be used in patients with severe renal impairment (see section 4.3). In patients with moderate renal impairment, Teriparatide SUN should be used with caution. No special caution is required for patients with mild renal impairment.
Patients with hepatic impairment
No data are available in patients with impaired hepatic function (see section 5.3). Therefore, Teriparatide SUN should be used with caution.
Paediatric population and young adults with open epiphyses
The safety and efficacy of Teriparatide SUN in children and adolescents less than 18 years has not been established. Teriparatide SUN should not be used in paediatric patients (less than 18 years), or young adults with open epiphyses.
Elderly patients
Dose adjustment based on age is not required (see section 5.2).
Method of administration
Teriparatide SUN should be administered once daily by subcutaneous injection in the thigh or abdomen.
Patients must be trained to use the proper injection techniques (see section 6.6). How to use Teriparatide SUN 20 micrograms/80 microliters solution for injection in pre-filled pen is also available to instruct patients on the correct use of the pen.
- hypersensitivity to the active substance or to any of the excipients listed in section 6.1
- pregnancy and breast-feeding (see sections 4.4 and 4.6)
- pre-existing hypercalcaemia
- severe renal impairment
- metabolic bone diseases (including hyperparathyroidism and Paget's disease of the bone) other than primary osteoporosis or glucorticoid-induced osteoporosis.
- unexplained elevations of alkaline phosphatase
- prior external beam or implant radiation therapy to the skeleton
- patients with skeletal malignancies or bone metastases should be excluded from treatment with teriparatide.
Traceability
In order to improve the traceability of biological medicinal products, the name and batch number of the administered medicinal product should be clearly recorded.
Serum and urine calcium
In normocalcaemic patients, slight and transient elevations of serum calcium concentrations have been observed following teriparatide injection. Serum calcium concentrations reach a maximum between 4 and 6 hours and return to baseline by 16 to 24 hours after each dose of teriparatide. Therefore, if blood samples for serum calcium measurements are taken, this should be done at least 16 hours after the most recent Teriparatide SUN injection. Routine calcium monitoring during therapy is not required.
Teriparatide SUN may cause small increases in urinary calcium excretion, but the incidence of hypercalciuria did not differ from that in the placebo-treated patients in clinical trials.
Urolithiasis
Teriparatide SUN has not been studied in patients with active urolithiasis. Teriparatide SUN should be used with caution in patients with active or recent urolithiasis because of the potential to exacerbate this condition.
Orthostatic hypotension
In short-term clinical studies with Teriparatide SUN, isolated episodes of transient orthostatic hypotension were observed. Typically, an event began within 4 hours of dosing and spontaneously resolved within a few minutes to a few hours. When transient orthostatic hypotension occurred, it happened within the first several doses, was relieved by placing subjects in a reclining position, and did not preclude continued treatment.
Renal impairment
Caution should be exercised in patients with moderate renal impairment.
Younger adult population
Experience in the younger adult population, including premenopausal women, is limited (see section 5.1). Treatment should only be initiated if the benefit clearly outweighs risks in this population.
Women of childbearing potential should use effective methods of contraception during use of Teriparatide SUN. If pregnancy occurs, Teriparatide SUN should be discontinued.
Duration of treatment
Studies in rats indicate an increased incidence of osteosarcoma with long-term administration of teriparatide (see section 5.3). Until further clinical data become available, the recommended treatment time of 24 months should not be exceeded.
Sodium
This medicinal product contains less than 1 mmol sodium (23 mg) per maximum daily dose, that is to say 'sodium- free'.
In a study of 15 healthy subjects administered digoxin daily to steady state, a single Teriparatide SUN dose did not alter the cardiac effect of digoxin. However, sporadic case reports have suggested that hypercalcaemia may predispose patients to digitalis toxicity. Because Teriparatide SUN transiently increases serum calcium, Teriparatide SUN should be used with caution in patients taking digitalis.
Teriparatide SUN has been evaluated in pharmacodynamic interaction studies with hydrochlorothiazide. No clinically significant interactions were noted.
Co-administration of raloxifene or hormone replacement therapy with Teriparatide SUN did not alter the effects of Teriparatide SUN on serum or urine calcium or on clinical adverse events.
Women of childbearing potential / Contraception in females
Women of childbearing potential should use effective methods of contraception during use of Teriparatide SUN. If pregnancy occurs, Teriparatide SUN should be discontinued.
Pregnancy
Teriparatide SUN is contraindicated for use during pregnancy (see section 4.3).
Breast-feeding
Teriparatide SUN is contraindicated for use during breast-feeding. It is not known whether teriparatide is excreted in human milk.
Fertility
Studies in rabbits have shown reproductive toxicity (see section 5.3). The effect of teriparatide on human foetal development has not been studied. The potential risk for humans is unknown.
Teriparatide SUN has no or negligible influence on the ability to drive and use machines. Transient, orthostatic hypotension or dizziness was observed in some patients. These patients should refrain from driving or the use of machines until symptoms have subsided.
Summary of the safety profile
The most commonly reported adverse reactions in patients treated with Teriparatide SUN are nausea, pain in limb, headache and dizziness.
Tabulated list of adverse reactions
Of patients in the teriparatide trials, 82.8 % of the Teriparatide SUN patients and 84.5 % of the placebo patients reported at least 1 adverse event.
The adverse reactions associated with the use of teriparatide in osteoporosis clinical trials and post- marketing exposure are summarised in the table below. The following convention has been used for the classification of the adverse reactions: very common (≥ 1/10), common (≥ 1/100 to <1/10), uncommon (≥ 1/1 000 to <1/100), rare (≥ 1/10 000 to <1/1 000) very rare (<1/10 000).
Blood and lymphatic system disorders
Common:
Anaemia
Immune system disorder
Rare:
Anaphylaxis
Metabolism and nutrition disorders
Common:
Hypercholesterolaemia
Uncommon:
Hypercalcaemia greater than 2.76 mmol/l, hyperuricemia
Rare:
Hypercalcaemia greater than 3.25 mmol/l
Psychiatric disorders
Common:
Depression
Nervous system disorders
Common:
Dizziness, headache, sciatica, syncope
Ear and labyrinth disorders
Common:
Vertigo
Cardiac disorders
Common:
Palpitations
Uncommon:
Tachycardia
Vascular disorders
Common:
Hypotension
Respiratory, thoracic and mediastinal disorders
Common:
Dyspnoea
Uncommon:
Emphysema
Gastrointestinal disorders
Common:
Nausea, vomiting, hiatus hernia, gastroesophageal reflux disease
Uncommon:
Haemorrhoids
Skin and subcutaneous tissue disorders
Common:
Sweating increased
Musculoskeletal and connective tissue disorders
Very common:
Pain in limb
Common:
Muscle cramps
Uncommon:
Myalgia, arthralgia, back cramp/pain*
Renal and urinary disorders
Uncommon:
Urinary incontinence, polyuria, micturition urgency, nephrolithiasis
Rare:
Renal failure/impairment
General disorders and administration site conditions
Common:
Fatigue, chest pain, asthenia, mild and transient injection site events, including pain, swelling, erythema, localised bruising, pruritis and minor bleeding at injection site
Uncommon:
Injection site erythema, injection site reaction
Rare:
Possible allergic events soon after injection: acute dyspnoea, oro/facial oedema, generalised urticaria, chest pain, oedema (mainly peripheral)
Investigations
Uncommon:
Weight increased, cardiac murmur, alkaline phosphatase increase
*Serious cases of back cramp or pain have been reported within minutes of the injection.
Description of selected adverse reactions
In clinical trials the following reactions were reported at a ≥ 1 % difference in frequency from placebo: vertigo, nausea, pain in limb, dizziness, depression, dyspnoea.
Teriparatide SUN increases serum uric acid concentrations. In clinical trials, 2.8 % of Teriparatide SUN patients had serum uric acid concentrations above the upper limit of normal compared with 0.7 % of placebo patients. However, the hyperuricemia did not result in an increase in gout, arthralgia, or urolithiasis.
In a large clinical trial, antibodies that cross-reacted with teriparatide were detected in 2.8 % of women receiving Teriparatide SUN. Generally, antibodies were first detected following 12 months of treatment and diminished after withdrawal of therapy. There was no evidence of hypersensitivity reactions, allergic reactions, effects on serum calcium, or effects on Bone Mineral Density (BMD) response.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Signs and symptoms
Teriparatide SUN has been administered in single doses of up to 100 micrograms and in repeated doses of up to 60 micrograms/day for 6 weeks.
The effects of overdose that might be expected include delayed hypercalcaemia and risk of orthostatic hypotension. Nausea, vomiting, dizziness, and headache can also occur.
Overdose experience based on post-marketing spontaneous reports
In post-marketing spontaneous reports, there have been cases of medication error where the entire contents (up to 800 mcg) of the teriparatide pen have been administered as a single dose. Transient events reported have included nausea, weakness/lethargy and hypotension. In some cases, no adverse events occurred as a result of the overdose. No fatalities associated with overdose have been reported.
Overdose management
There is no specific antidote for Teriparatide SUN. Treatment of suspected overdose should include transitory discontinuation of Teriparatide SUN, monitoring of serum calcium, and implementation of appropriate supportive measures, such as hydration.
Ask anything about Teriparatide SUN 20 micrograms/80 microliters solution for injection in pre-filled pen. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.